StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.98MP/E –Yield –

Lyell Immunopharma enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Lyell Immunopharma's enterprise value was $190.37M on Nov 11, 2026, against $143.43M a year earlier. Over the last 5 years it ranged from -$289.10M to $1.24B, with a median of $54.20M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$190.37M-30.6%
2025Dec 31, 2025$274.24M–
2024Dec 31, 2024-$276.35M–
2023Dec 29, 2023-$86.81M-140.1%
2022Dec 30, 2022$216.73M-82.5%
2021Dec 31, 2021$1.24B–

More Lyell Immunopharma figures

See a number that looks wrong?